Revision: March 2, 2010, midnight
SB 510 – AS INTRODUCED
2010 SESSION
01/09
SENATE BILL 510
AN ACT establishing a commission to evaluate the parity between oral and intravenous chemotherapy.
SPONSORS: Sen. Houde, Dist 5; Sen. Merrill, Dist 21; Sen. Sgambati, Dist 4; Rep. Houde-Quimby, Sull 1; Rep. Hammond, Hills 3; Rep. Nord, Rock 1
COMMITTEE: Health and Human Services
This bill establishes a commission to evaluate the parity between oral and intravenous chemotherapy.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Explanation: Matter added to current law appears in bold italics.
Matter removed from current law appears [in brackets and struckthrough.]
Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.
10-2957
01/09
STATE OF NEW HAMPSHIRE
In the Year of Our Lord Two Thousand Ten
AN ACT establishing a commission to evaluate the parity between oral and intravenous chemotherapy.
Be it Enacted by the Senate and House of Representatives in General Court convened:
1 Commission Established. There is established a commission to study the parity between oral and intravenous chemotherapy.
2 Membership and Compensation.
I. The members of the commission shall be as follows:
(a) One member of the senate who shall be from the senate health and human services committee, appointed by the president of the senate.
(b) Two members of the house of representatives, one of whom shall be from the house finance committee and one of whom shall be from the house commerce and consumer affairs committee, appointed by the speaker of the house of representatives.
(c) The commissioner of the department of health and human services, or designee.
(d) The insurance commissioner, or designee.
(e) A pharmacist, appointed by the pharmacy board.
(f) A representative of the Norris Cotton Cancer Center, Dartmouth-Hitchcock, appointed by the center.
(g) A representative of an oncology clinic within a community hospital and a representative of a free standing oncology practice, appointed by the governor.
(h) A representative of the American Cancer Society, appointed by that organization.
(i) A cancer clinical resource coordinator or social worker, appointed by the commissioner of the department of health and human services.
II. Legislative members of the commission shall receive mileage at the legislative rate when attending to the duties of the commission.
3 Duties. The commission shall:
I. Collect, compile, and analyze data to determine whether a disparity between coverage for chemotherapy treatments exists.
II. Receive, if applicable, testimony from patients, providers, and other persons deemed necessary by the commission.
III. Determine, to the extent possible, the cost to insurers of requiring parity.
IV. Survey how other jurisdictions have addressed this issue.
4 Chairperson; Quorum. The members of the commission shall elect a chairperson from among the members. The first meeting of the commission shall be called by the first-named senate member. The first meeting of the commission shall be held within 45 days of the effective date of this section. Five members of the commission shall constitute a quorum.
5 Report. The commission shall make an interim report on or before November 1, 2010 and a final report on or before November 1, 2011 together with its findings and any recommendations for proposed legislation to the president of the senate, the speaker of the house of representatives, the senate clerk, the house clerk, the governor, and the state library.
6 Effective Date. This act shall take effect upon its passage.